Announcements Trials
Browse Landscape

Phase

Phase 2 15Phase 3 10Phase 1 3Phase 2/3 2Phase 1/2 2Phase EARLY_PHASE1 1

Status

Terminated 1Not yet recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2

Conditions

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Burkitt Lymphoma 1

Interventions

pembrolizumab 38Specimen Handling 37Magnetic Resonance Spectroscopy 26Biopsy 26Cyclophosphamide 25Carboplatin 25fludarabine 21Nivolumab 20Gemcitabine 18Dexamethasone 18Paclitaxel 15Rituximab 13Bevacizumab 13Pemetrexed 12Docetaxel 12atezolizumab 11Cisplatin 11Lenalidomide 10Ipilimumab 10Fulvestrant 10venetoclax 9Prednisone 9Oxaliplatin 9olaparib 8fludarabine phosphate 8belantamab mafodotin 8Temozolomide 8Injections 8Fluorouracil 8abemaciclib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Methotrexate × 30 days × Clear all
NCT07387926 2026-05-19

Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL)

Novartis

Phase 1/2 Not yet recruiting
50 enrolled
LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03808610 2026-05-13

Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia

M.D. Anderson Cancer Center

Phase 1/2 Terminated
53 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡